ORGO (Organogenesis Holdings) Inventory Turnover: 0.89 (As of Mar. 2026)

What is Organogenesis Holdings Inventory Turnover?

Organogenesis Holdings ORGO -3.08% 67 Inventory Turnover is 0.89 as of Mar. 2026. GuruFocus rates ORGO with a GF Score™ of 67/100 and a GF Value™ of $3.10 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Organogenesis Holdings's Cost of Goods Sold for the three months ended in Mar. 2026 was $25.8 Mil. Organogenesis Holdings's Average Total Inventories for the quarter that ended in Mar. 2026 was $29.0 Mil. Organogenesis Holdings's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.89.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Organogenesis Holdings's Days Inventory for the three months ended in Mar. 2026 was 102.77.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Organogenesis Holdings's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.80.

Organogenesis Holdings (NAS:ORGO) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Organogenesis Holdings's Days Inventory for the three months ended in Mar. 2026 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2026 )	/	Cost of Goods Sold (Q: Mar. 2026 )	*	Days in Period
	=	29.026	/	25.772	*	365 / 4
	=	102.77

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Organogenesis Holdings's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	29.026	/	36.25
	=	0.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

Organogenesis Holdings Inventory Turnover Related Terms

Organogenesis Holdings Inventory Turnover Historical Data

* Premium members only.

The historical data trend for Organogenesis Holdings's Inventory Turnover can be seen below:

Organogenesis Holdings Inventory Turnover Chart

Organogenesis Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Inventory Turnover

Get a 7-Day Free Trial

4.32

4.22

4.02

4.25

4.93

Organogenesis Holdings Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Inventory Turnover	Get a 7-Day Free Trial															0.85	0.89	1.00	1.44	0.89

67GF Score

Organogenesis Holdings Inc ORGO

Inventory Turnover is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Organogenesis Holdings Inventory Turnover Calculation

Organogenesis Holdings's Inventory Turnover for the fiscal year that ended in Dec. 2025 is calculated as

	Inventory Turnover (A: Dec. 2025 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (A: Dec. 2025 )	/ (	(Total Inventories (A: Dec. 2024 )	+	Total Inventories (A: Dec. 2025 ))	/	count )
=	137.522	/ (	(26.219	+	29.627)	/	2 )
=	137.522	/	27.923
=	4.93

Organogenesis Holdings's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

	Inventory Turnover (Q: Mar. 2026 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (Q: Mar. 2026 )	/ (	(Total Inventories (Q: Dec. 2025 )	+	Total Inventories (Q: Mar. 2026 ))	/	count )
=	25.772	/ (	(29.627	+	28.425)	/	2 )
=	25.772	/	29.026
=	0.89

Frequently Asked Questions Learn more about Inventory Turnover →

What does a Inventory Turnover of 0.89 mean?

Organogenesis Holdings (ORGO) has a Inventory Turnover of 0.89 as of Mar. 2026. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Organogenesis Holdings and its competitors.

Is Organogenesis Holdings' Inventory Turnover too high?

Organogenesis Holdings' current Inventory Turnover is 0.89. Overall, Organogenesis Holdings has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Organogenesis Holdings' Inventory Turnover compare to TKNO and AKBA?

Organogenesis Holdings' Inventory Turnover of 0.89 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Inventory Turnover for a Drug Manufacturers company?

A good Inventory Turnover depends on the Drug Manufacturers industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Inventory Turnover mean?

A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Organogenesis Holdings and its competitors. Organogenesis Holdings's current Inventory Turnover is 0.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Organogenesis Holdings stock overvalued right now?

Based on GuruFocus' analysis, Organogenesis Holdings (ORGO) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.10, compared to a current price of $2.36 — trading 23.9% below its estimated fair value. The current Inventory Turnover is 0.89. Organogenesis Holdings' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Inventory Turnover calculated?

Inventory Turnover is calculated from a company's financial statements. For Organogenesis Holdings (ORGO), the current Inventory Turnover is 0.89 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Organogenesis Holdings (ORGO) Overvalued in 2026?

Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued. The current stock price of $2.36 is trading 23.9% below its estimated GF Value™ of $3.10. GuruFocus considers Organogenesis Holdings to be Modestly Undervalued.

Key valuation signals for ORGO:

Inventory Turnover: 0.89
GF Value™: $3.10 vs. price of $2.36 (23.9% below fair value)
GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the ORGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Organogenesis Holdings Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies TKNO AKBA SIGA ELTP ANIK LFCR EBS DERM NIKA EOLS XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges 2PQ:Germany

Address 85 Dan Road, Canton, MA, USA, 02021

Website https://www.organogenesis.com

Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.

67GF Score

Get the complete analysis for ORGO

Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.36

Price

$3.10

GF Value

View ORGO Analysis

See Inventory Turnover data for all stocks →